For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Group newsletter: CCTG Connection

Archived Bulletins

April 22, 2020

Published: April 22, 2020
Category: Trials

CCTG Planned Trials

ALC5 - Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial) More >>

Read More

Published: April 22, 2020
Category: Trials

CRC9 (NCT04068103), Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA), has been centrally activated.

Read More

Published: April 22, 2020
Category: Group updates
COVID-19 Update: CCTG guidance documents and updated FAQ

CCTG has developed guidance documents to facilitate continuing patients on trials or how to modify (and document) protocol requirements for individual patient management as needed.

Please note that an updated Frequently Asked Questions (FAQs) document has been posted to the CCTG COVID-19 members webpage. Also new are posted links to the previously communicated important memos dated 2020MAR17, 2020MAR27 and 2020APR06.

Read More

Published: April 22, 2020
Category: News
NCTN group chairs: Clinical care amid COVID-19 pandemic

A guest editorial first published in the "Cancer Letter"

 

While the National Clinical Trials Network (NCTN) groups remain open for business during the pandemic, it’s not business as usual. For good reason, clinical trials are taking a backseat to clinical care. Leadership and members themselves face significant challenges treating oncology patients, as attention and resources are diverted to minister to those with COVID-19.

Read More

Published: April 22, 2020
Category: News

CCTG has been made aware of an opportunity that may be of interest to our member centres during this COVID-19 pandemic. Jonathan Loree and colleagues at BC Cancer have developed a protocol to help Canadian centres track outcomes among patients with cancer who develop COVID-19.

Read More

Published: April 22, 2020
Category: Publications

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia

Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodriguez, Tanya Skamene, Lawrence Panasci, Bingshu E. Chen & Annette E. Hay

Read More

April 08, 2020

Published: April 08, 2020
Category: Trials

The CCTG BR31 (NCT02273375) trial, A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer has been closed to accrual to the main study.

The purpose of this study was to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Read More

Published: April 08, 2020
Category: Group updates
COVID-19 Update: Trial addenda and new EDC form

This past week the central office has continued to support CCTG network activities including addressing impacts of COVID-19.

CCTG regulatory/ethics compliance and trial teams rolled out COVID-19 addenda for all trials. These addenda have been added to all CCTG trial pages to support sites and trial teams in our network. We are also incorporating an EDC form for the collection of COVID-19 information for designated trials.

Read More